Enanta Pharmaceuticals to Present at Two September Investor Conferences
Event summary
- Enanta Pharmaceuticals will participate in two investor conferences in September 2026.
- Fireside chat at Baird 2026 Global Healthcare Conference on September 15, 2026, at 1:25 p.m. ET.
- Fireside chat at H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, at 8:00 a.m. ET.
- Live webcasts will be available on Enanta’s website, with replays archived for at least 30 days.
The big picture
Enanta Pharmaceuticals is leveraging investor conferences to showcase its pipeline of small molecule drugs for viral infections and immunological diseases. The company’s focus on RSV and inflammatory diseases aligns with broader industry trends toward targeted therapies. Enanta’s ongoing royalty revenue from AbbVie’s HCV products provides a financial cushion, but its long-term success hinges on the advancement of its clinical-stage programs.
What we're watching
- Pipeline Progress
- How Enanta’s RSV and immunology pipeline developments will impact investor sentiment.
- Royalty Revenue
- Whether AbbVie’s HCV product royalties will continue to support Enanta’s operations.
- Market Positioning
- The pace at which Enanta can establish itself as a leader in viral and immunological treatments.
Related topics